Today: 1 May 2026
BP stock jumps 3% to start 2026 as oil traders eye OPEC+ and BP’s next results
4 January 2026
1 min read

BP stock jumps 3% to start 2026 as oil traders eye OPEC+ and BP’s next results

NEW YORK, Jan 3, 2026, 17:26 ET — Market closed

  • BP’s U.S.-listed shares closed at $35.83 on Friday, up about 3.2%
  • Oil ended the week lower but remained range-bound ahead of an OPEC+ meeting on Sunday
  • BP disclosed updated total voting rights in a Jan. 2 filing; investors now look to February results

BP’s U.S.-listed shares rose about 3.2% on Friday, closing at $35.83, as energy names firmed in the first session of 2026.

The move mattered because oil prices remain the biggest day-to-day driver for integrated majors like BP, with traders looking for clues on supply discipline after crude’s steep 2025 slide.

Markets also begin the year with positioning around near-term oil catalysts, including an OPEC+ meeting this weekend, and the next round of company updates on earnings and shareholder returns.

Oil prices settled slightly lower on Friday as investors weighed oversupply concerns against geopolitical risks. Brent futures closed at $60.75 a barrel and U.S. West Texas Intermediate at $57.32; OPEC+ is due to meet on Sunday, with traders expecting the group to keep pausing output increases in the first quarter, Sparta Commodities analyst June Goh said. “Oil prices are locked in this long-term trading range,” said Phil Flynn, senior analyst at Price Futures Group. Reuters

BP outpaced several oil-linked peers on the day. Exxon Mobil’s shares rose 1.92%, while Eni’s U.S.-listed shares gained 2.90% and Galp Energia’s ADR added 1.78%, MarketWatch data showed.

BP also posted trading ranges that drew attention from short-term investors, with Friday’s intraday low around $35 and a session high just under $35.85.

Separately, BP said in a Form 6-K dated Jan. 2 that its total voting rights stood at 15,633,962,785 as of Dec. 31, 2025. The filing said BP had 15,628,880,285 ordinary shares in issue excluding treasury shares, and 857,432,709 ordinary shares held in treasury that do not count for dividends or votes.

Total voting-rights updates are routine for U.K.-listed companies, helping shareholders calculate when they must disclose stake changes under U.K. transparency rules, the filing showed.

Broader markets ended mixed on Friday, while U.S. Treasury yields moved higher and the dollar firmed. Reuters reported the Dow rose 0.66% and the Nasdaq slipped 0.03% in the first session of 2026.

Before the next session on Monday, Jan. 5, investors are likely to take cues from any headlines out of Sunday’s OPEC+ meeting and from weekend developments tied to energy supply risks and sanctions.

The next scheduled BP-specific catalyst is its fourth-quarter 2025 results and dividend announcement on Feb. 10, according to the company’s investor events listing. Investors typically focus on cash flow, buybacks and dividend policy in those updates.

For technical traders, Friday’s $35 area and the stock’s recent highs are the near-term levels in view after the sharp start-of-year move.

Stock Market Today

  • Lake Shore Bancorp (LSBK) Ex-Dividend Date Set for May 4, 2026
    May 1, 2026, 11:24 AM EDT. Lake Shore Bancorp Inc (LSBK) will go ex-dividend on May 4, 2026. The quarterly dividend is $0.09 per share, about 0.57% of its recent $15.92 stock price. This means shares may open roughly 0.57% lower on that date, all else equal. The dividend pays out on May 13, 2026, and the company's current annualized dividend yield is approximately 2.26%. LSBK shares have traded between $11.50 and $16.28 over the past 52 weeks, with the latest close near the high at $15.92. Investors track such metrics to gauge dividend sustainability and stock performance. On Friday, shares edged up 0.2%.

Latest article

Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise

Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise

1 May 2026
BOSTON, May 1, 2026, 11:03 (EDT) Cue Biopharma shares jumped in Friday morning trading after the Boston biotechnology firm announced a new allergy drug license, a $30 million private placement and the appointment of Shao-Lee Lin as chief executive. The shares were up 91.4% at $28.21 at 11:03 a.m. EDT, with Nasdaq trading open, after closing Thursday at $14.74, market data showed. The stock had opened as high as $33.75 before paring gains. The move matters now because Cue is trying to reset its business around clinical-stage immunology assets after a turbulent period for the stock. Last week it implemented
Atlassian Corporation Stock Jumps 22% as AI-Led Earnings Beat Tests SaaS Selloff

Atlassian Corporation Stock Jumps 22% as AI-Led Earnings Beat Tests SaaS Selloff

1 May 2026
Atlassian shares surged 22% Friday after the company beat quarterly estimates and raised its annual revenue forecast. Fiscal Q3 revenue climbed 32% to $1.787 billion, but Atlassian posted a $98.4 million net loss after restructuring charges. Cloud revenue rose 29% as customers expanded Jira use and adopted more AI features. Remaining performance obligations jumped 37% to $4.0 billion.
S&P Global stock drops again to start 2026 — here’s what SPGI investors watch next
Previous Story

S&P Global stock drops again to start 2026 — here’s what SPGI investors watch next

MARA stock jumps 10% as bitcoin miners rebound — what traders watch before Monday
Next Story

MARA stock jumps 10% as bitcoin miners rebound — what traders watch before Monday

Go toTop